Clinical determinants and biomarkers for predicting chemotherapeutic response in advanced non-small cell lung cancer: a single-center retrospective study [0.03%]
晚期非小细胞肺癌化疗疗效的临床影响因素及预测标志物：单中心回顾性研究
Ling Zhang,Wei Li,Yidong Wang et al.
Ling Zhang et al.
Objective: To evaluate clinical determinants and predictive biomarkers for response to platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). ...
Dupilumab improves symptoms and quality of life in patients with eosinophilic esophagitis: a plain language summary [0.03%]
Dupilumab可改善嗜酸性食管炎患者的症状和生活质量：简易语言摘要
Mary Jo Strobel,Jonathan M Spergel,Mirna Chehade et al.
Mary Jo Strobel et al.
Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy [0.03%]
下一代癌症免疫治疗：CAR-T细胞疗法的前景
Harshad S Kapare,Rutuja Jadhav,Pawan N Karwa et al.
Harshad S Kapare et al.
Chimeric antigen receptor (CAR) T-cell treatment has developed among major substantial improvements for modern cancer treatment, providing sustained responses in patients with otherwise resistant blood cancers. This method comprises of pati...
Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager [0.03%]
靶向DLL3的双特异性T细胞接合器tarlatamab治疗复发性小细胞肺癌
Prodromos Koutoukoglou,Giannis Mountzios
Prodromos Koutoukoglou
Relapsed small cell lung cancer (SCLC) is widely considered as a difficult-to-treat disease with an adverse prognosis and scarce therapeutic options, especially in the case of platinum-resistance. Tarlatamab (IMDELLTRA™), a first-in-class,...
Oncolytic viruses in brain cancer therapy: advances, challenges, and clinical trial outcomes [0.03%]
溶瘤病毒在脑癌治疗中的进展、挑战及临床试验结果
Yaser Arjeini,Sara Khalili Dermani,Sanaz Sadeh et al.
Yaser Arjeini et al.
Malignant intracranial tumors are a major cause of morbidity and mortality across age groups. To assess recent progress in glioblastoma (GBM) oncolytic virotherapy, literature was searched in PubMed and Google Scholar using the keywords gli...
ELAVL1 increases macrophage M1 polarization via upregulating S100A8 to promote Crohn's disease progression [0.03%]
ELAVL1通过上调S100A8促进单核细胞M1极化从而推动克罗恩病进展
Lin Jia,Yingtai Chen,Ying Lu
Lin Jia
Objective: This study aims to investigate the impact and molecular mechanism of ELAVL1 in promoting macrophage M1 polarization in Crohn's disease (CD) by upregulating S100A8 expression. ...
Could immunotherapy be a feasible treatment option for patient's suffering from chronic epilepsy? [0.03%]
免疫治疗可能是慢性癫痫患者的可行治疗方法吗？
Colin P Doherty
Colin P Doherty
Correction [0.03%]
改正
Published Erratum
Immunotherapy. 2026 Apr 28:1. DOI:10.1080/1750743X.2026.2665946 2026
Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials [0.03%]
帕博利珠单抗联合化疗治疗低PD-L1表达的晚期或转移性非小细胞肺癌：随机对照试验的系统评价和meta分析
Akhil Deepak Vatvani,Gilbert Lazarus,Reyad Al Jabiri et al.
Akhil Deepak Vatvani et al.
Introduction: Pembrolizumab plus chemotherapy is widely used as first-line treatment for advanced NSCLC, but its benefit in patients with low PD-L1 expression remains uncertain. This study evaluated pembrolizumab plus che...
First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysis [0.03%]
舒格利单抗联合化疗对比单纯化疗一线治疗晚期非小细胞肺癌的的成本效益分析：基于中国的研究
Zixuan Zhang,Kehui Meng,Meiyu Wu et al.
Zixuan Zhang et al.
Objective: To assess the cost-effectiveness of sugemalimab plus chemotherapy as first-line treatment for metastatic Non-small cell lung cancer(NSCLC) in China. ...